Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The stock has a good momentum. Aurinia Pharmaceuticals Inc is not very popular among insiders. Aurinia Pharmaceuticals Inc is a good stock to invest in, but there are better stocks to choose.

Aurinia Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company, which engages in...

News

Aurinia Announces Board Restructuring

Business Wire Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it has restructured its Board of Directors (the Board) to further align the Company with shareholder...\n more…

Aurinia Pharmaceuticals call volume above normal and directionally bullish

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Simply Wall St Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) shareholders have had their patience rewarded with a 30% share price jump...\n more…

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Business Wire Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announced today that the first participant has been dosed in a Phase 1a single ascending dose (SAD) study of AUR200, a...\n more…

Banque Cantonale Vaudoise Acquires 5,410 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Ticker Report Banque Cantonale Vaudoise increased its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 126.6% during the 2nd quarter, according to its most recent Form...\n more…